BIOMAT Database Logo BIOMAT Database Logo

Pharmaceutical development of a parenteral lyophilized formulation of the novel indoloquinone antitumor agent EO9. 1994

J D Jonkman-de Vries, and H Talsma, and R E Henrar, and J J Kettenes-van den Bosch, and A Bult, and J H Beijnen
Department of Pharmacy, Slotervaart Hospital/Netherlands Cancer Institute, Amsterdam.

The aim of this study was to design a stable parenteral dosing form of the investigational cytotoxic drug, encoded EO9. EO9 exhibits poor aqueous solubility and stability characteristics. Freeze-drying was selected as the manufacturing process. Differential scanning calorimetry studies were conducted to determine the freeze-drying cycle parameters. A stable lyophilized formulation of EO9 was developed. The prototype, containing 8.0 mg EO9 and 200 mg lactose/vial, was found to be the optimal formulation in terms of solubility, length of the freeze-drying cycle, stability, and dosing requirements for phase I clinical trials. Quality control of the freeze-dried formulation showed that the manufacturing process does not change the integrity of EO9. Shelf-life studies demonstrated that the formulation remains stable for at least 1 year when stored at +4 degrees C in a dark environment.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D011786 Quality Control A system for verifying and maintaining a desired level of quality in a product or process by careful planning, use of proper equipment, continued inspection, and corrective action as required. (Random House Unabridged Dictionary, 2d ed) Control, Quality,Controls, Quality,Quality Controls
D011809 Quinones Hydrocarbon rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.
D002152 Calorimetry, Differential Scanning Differential thermal analysis in which the sample compartment of the apparatus is a differential calorimeter, allowing an exact measure of the heat of transition independent of the specific heat, thermal conductivity, and other variables of the sample. Differential Thermal Analysis, Calorimetric,Calorimetric Differential Thermal Analysis,Differential Scanning Calorimetry,Scanning Calorimetry, Differential
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D004355 Drug Stability The chemical and physical integrity of a pharmaceutical product. Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs
D004356 Drug Storage The process of keeping pharmaceutical products in an appropriate location. Drug Storages,Storage, Drug,Storages, Drug
D005612 Freeze Drying Method of tissue preparation in which the tissue specimen is frozen and then dehydrated at low temperature in a high vacuum. This method is also used for dehydrating pharmaceutical and food products. Lyophilization,Drying, Freeze,Dryings, Freeze,Freeze Dryings,Lyophilizations
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001388 Aziridines Saturated azacyclopropane compounds. They include compounds with substitutions on CARBON or NITROGEN atoms. Ethyleneimines,Azacyclopropanes, Saturated,Dimethyleneimines,Saturated Azacyclopropanes

Related Publications

J D Jonkman-de Vries, and H Talsma, and R E Henrar, and J J Kettenes-van den Bosch, and A Bult, and J H Beijnen
Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine.
January 2000, PDA journal of pharmaceutical science and technology,
J D Jonkman-de Vries, and H Talsma, and R E Henrar, and J J Kettenes-van den Bosch, and A Bult, and J H Beijnen
Purity determinations in the bulk drug of the novel indoloquinone antitumor agent EO9.
January 1996, Investigational new drugs,
J D Jonkman-de Vries, and H Talsma, and R E Henrar, and J J Kettenes-van den Bosch, and A Bult, and J H Beijnen
Pharmaceutical development and manufacturing of a parenteral formulation of a novel antitumor agent, VNP40101M.
August 2001, AAPS PharmSciTech,
J D Jonkman-de Vries, and H Talsma, and R E Henrar, and J J Kettenes-van den Bosch, and A Bult, and J H Beijnen
Development of a lyophilized parenteral pharmaceutical formulation of the investigational polypeptide marine anticancer agent kahalalide F.
September 2001, Drug development and industrial pharmacy,
J D Jonkman-de Vries, and H Talsma, and R E Henrar, and J J Kettenes-van den Bosch, and A Bult, and J H Beijnen
Pharmaceutical development of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum anticancer agent AP 5280.
October 2003, Drug development and industrial pharmacy,
J D Jonkman-de Vries, and H Talsma, and R E Henrar, and J J Kettenes-van den Bosch, and A Bult, and J H Beijnen
Pharmaceutical development of a parenteral lyophilized formulation of the antimetastatic ruthenium complex NAMI-A.
November 2002, International journal of pharmaceutics,
J D Jonkman-de Vries, and H Talsma, and R E Henrar, and J J Kettenes-van den Bosch, and A Bult, and J H Beijnen
Pharmaceutical development of a parenteral formulation of the novel anti-tumor agent carzelesin (U-80,244).
January 1994, Investigational new drugs,
J D Jonkman-de Vries, and H Talsma, and R E Henrar, and J J Kettenes-van den Bosch, and A Bult, and J H Beijnen
The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9.
July 1991, Cancer communications,
J D Jonkman-de Vries, and H Talsma, and R E Henrar, and J J Kettenes-van den Bosch, and A Bult, and J H Beijnen
Pharmaceutical development, quality control, stability and compatibility of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum antineoplastic agent AP5346.
October 2006, Die Pharmazie,
J D Jonkman-de Vries, and H Talsma, and R E Henrar, and J J Kettenes-van den Bosch, and A Bult, and J H Beijnen
Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9.
April 1996, General pharmacology,
Copied contents to your clipboard!